Advertisement

Search Results

Advertisement



Your search for all items matches 35028 pages

Showing 1 - 50


breast cancer

Symptom-Detected Breast Cancers May Be Linked to Higher Mortality and Advanced Disease Risk

Whether a patient’s breast cancer was detected through symptoms or routine screening mammography significantly affected their risk for advanced disease or death, according to a study published recently in Radiology: Imaging Cancer. Patients with symptom-detected breast cancer had higher odds of...

hematologic malignancies
immunotherapy
genomics/genetics
global cancer care

ASH 2025 Awardees: Hematologists to Be Honored With Highest Distinctions

The American Society of Hematology (ASH) announced that it will recognize 11 hematologists who have made notable contributions to the field with several honorific awards and prestigious lectures at the 2025 ASH Annual Meeting & Exposition in Orlando, Florida, from December 6–9, 2025. The...

breast cancer

Case 3: Leptomeningeal Disease in HER2-Positive Breast Cancer

This is Part 3 of Novel Therapies for HER2-Positive Breast Cancer Brain Metastases, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Carey Anders, Rani Bansal, and Sarah Sammons discuss the treatment of a patient with a history...

Case 2: Intracranial Progression on ADC Therapy

This is Part 2 of Novel Therapies for HER2-Positive Breast Cancer Brain Metastases, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Carey Anders, Rani Bansal, and Sarah Sammons discuss the treatment of a patient with a history...

breast cancer
genomics/genetics

How a Commonly Inherited Genetic Alteration Is Driving Breast Cancer Metastasis and Predicting Survival

A common germline variant in the proprotein convertase subtilisin/kexin type 9 (PCSK9) (rs562556, V474I) gene rather than a mutation in a breast cancer tumor may be the driving force in significantly increasing the risk of breast cancer metastasis and reducing survival in women with the disease....

breast cancer

Case 1: Isolated Brain Relapse in HER2-Positive Breast Cancer

This is Part 1 of Novel Therapies for HER2-Positive Breast Cancer Brain Metastases, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Carey Anders, Rani Bansal, and Sarah Sammons discuss the treatment of a patient with a cT2N1,...

issues in oncology

Establishing Novel Models of Interdisciplinary Care to Improve Survival Outcomes in Patients With Cancer

Internationally renowned for her decades-long pioneering research in pancreatic cancer, in 2024, Diane M. Simeone, MD, left her positions as the Laura and Isaac Perlmutter Professor of Surgery and Pathology; Director, Pancreatic Cancer Center; and Associate Director of the Perlmutter Cancer Center...

issues in oncology

How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It

I’ve been a physician for several decades, seeing patients and functioning as a medical teacher; clinical, translational, and bench researcher; and administrator. Adapting to medical practice in three nations and several U.S. states has been quite challenging at different times, but I really think...

gastrointestinal cancer

Outcomes of Oncologic Extended Resection for Gallbladder Cancer: Results of a Global Analysis

In the United States, approximately 55% of patients with resected gallbladder cancer undergo oncologic surgery without additional systemic treatment. However, as gallbladder cancer progresses to T3 (locally or regionally advanced) or T4 (distant metastasis) disease, the tumor frequently infiltrates ...

multiple myeloma

Novel Tri-Specific Antibody Shows Efficacy and Safety in Refractory Myeloma

According to the initial findings of an ongoing first-in-human phase I trial, reported at the European Hematology Association (EHA) 2025 Congress, promising results have been shown for a novel off-the-shelf tri-specific antibody in the treatment of patients with multiple myeloma highly refractory...

leukemia
hematologic malignancies

Ropeginterferon Alfa-2b Outperforms Anagrelide as Second-Line Therapy for ET, Study Finds

Ropeginterferon alfa-2b demonstrated superior efficacy and safety compared with anagrelide as second-line therapy for patients with essential thrombocythemia (ET) who were intolerant or resistant to hydroxyurea, according to data from the phase III SURPASS-ET trial presented at the European...

hematologic malignancies
symptom management

Experimental Approach to GVHD Prophylaxis Offers Alternative to Standard Regimen

Prevention of graft-vs-host disease (GVHD) was superior with a cyclophosphamide/cyclosporin-based regimen compared with standard prophylaxis in patients receiving a matched-sibling donor stem cell transplant in a large Australian randomized trial, investigators reported at the European Hematology...

lymphoma

Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractory Follicular Lymphoma

Adding tafasitamab-cxix, an anti-CD19 monoclonal antibody, to lenalidomide and rituximab significantly prolonged progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented at the European Hematology Association (EHA) 2025 Congress (Abstract...

hematologic malignancies
lymphoma

Phase III POLARGO: Addition of Polatuzumab Vedotin Improves Overall Survival in Refractory DLBCL

Combining polatuzumab vedotin-piiq with rituximab, gemcitabine, and oxaliplatin (Pola–R-GemOx) significantly improved survival outcomes in patients with transplant-ineligible, relapsed or refractory diffuse large B-cell lymphoma (DLBCL) over standard R-GemOx alone, in the phase III POLARGO trial....

issues in oncology
survivorship

Contributors to Risk of Subsequent Neoplasms in Long-Term Survivors of Childhood Cancer

In a study reported in The Lancet Oncology, Neupane et al explored the question of whether cancer treatment and genetic predisposition are primary contributors to the risk of subsequent neoplasms (SNs) in long-term survivors of childhood cancers. Study Details The study involved data from the St....

pancreatic cancer

Addition of Tumor Treating Fields to Gemcitabine/Nab-Paclitaxel in Locally Advanced Pancreatic Adenocarcinoma

In a phase III trial (PANOVA-3) reported in the Journal of Clinical Oncology, Babiker et al examined the survival benefit of using tumor treating fields (TTFields) with gemcitabine/nab-paclitaxel in patients with unresectable locally advanced pancreatic adenocarcinoma. Study Details In the global...

lymphoma

FDA Approves CD19-Directed Antibody–Based Regimen for Follicular Lymphoma

On June 18, the U.S. Food and Drug Administration approved tafasitamab-cxix (Monjuvi), a CD19-directed cytolytic antibody, with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. inMIND Trial Efficacy was evaluated in inMIND (ClinicalTrials.gov identifier...

lymphoma
immunotherapy

Study Identifies Key LBCL Traits Tied to Greatest Benefit From CD19 CAR T-Cell Therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center have identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels of benefit from CD19-targeted chimeric antigen receptor (CAR) T cell therapy. In the study,...

cardio-oncology

Elevated Cardiac Biomarkers Associated With Increased Cancer Risk

Higher baseline levels of certain cardiac biomarkers were associated with an increased risk of future incidence of cancer, according to findings from a study published in the Journal of the American College of Cardiology: Advances. Higher incidence rates for all cancers were associated with higher ...

breast cancer

Regional Nodal Irradiation in Node-Negative Breast Cancer After Neoadjuvant Chemotherapy

In a phase III trial (NSABP B-51–RTOG 1304) reported in The New England Journal of Medicine, Mamounas et al examined regional nodal irradiation for activity in preventing invasive breast cancer recurrence or death from breast cancer in patients who had negative axillary nodes after neoadjuvant...

solid tumors
supportive care
symptom management

Psilocybin May Benefit Patients With Cancer, Major Depressive Disorder

A single dose of psilocybin may provide sustained reductions in depression and anxiety among patients with cancer and major depressive disorder, according to a recent study published by Agrawal et al in Cancer. Patients with cancer often experience depression. Psilocybin is a naturally occurring...

leukemia
lymphoma

Noncovalent BTK Inhibitor in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

In a phase III trial (BRUIN CLL-321) reported in the Journal of Clinical Oncology, Sharman et al compared treatment outcomes with the noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib vs investigator choice of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BR) in patients ...

solid tumors
colorectal cancer

Order of CRC Diagnosis May Influence Survival in Patients With Multiple Malignancies

The order of colorectal cancer diagnosis seems to have a significant impact on outcomes in patients with multiple primary malignancies, according to the results of a study of Surveillance, Epidemiology, and End Results (SEER) Program data. Findings from the study were published in the Journal of...

skin cancer

Four-Drug Induction Regimen Under Study in Advanced Melanoma With BRAF Mutation

In a phase II trial (EBIN) reported in The Lancet Oncology, Robert et al investigated the survival benefit of adding induction encorafenib/binimetinib to nivolumab/ipilimumab in patients with advanced melanoma with BRAF V600E or BRAF V600K mutation. Study Details In the open-label trial, 271...

breast cancer
global cancer care

Chronicling the Extraordinary Career of Stephen R. Grobmyer, MD, FACS, in Breast Cancer Research, Surgery, and Treatment

In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stephen R. Grobmyer, MD, FACS, about his clinical and research career in oncology, the challenges and rewards of moving to Abu Dhabi and building a state-of-the-art cancer center, and...

issues in oncology
legislation

Proposed Budget Cuts to Medicaid May Result in More Than 16,500 Medically Preventable Deaths Annually

The “One, Big, Beautiful” reconciliation bill making its way through Congress, which would make permanent provisions in the 2017 Tax Cuts and Jobs Act set to expire this year, includes massive cuts to Medicaid and Affordable Care Act marketplace coverage. An analysis of six potential Medicaid cuts...

skin cancer

Avelumab Plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma

In a phase II trial (Alliance A091802) reported in the Journal of Clinical Oncology, Zandberg et al investigated the survival benefit of adding cetuximab to avelumab in patients with advanced cutaneous squamous cell carcinoma. Study Details In the U.S. multicenter trial, 57 evaluable patients were...

breast cancer
lymphoma
issues in oncology
genomics/genetics

BRCA Mutations Could Increase Risk of Rare Lymphoma Among Women Who Received Textured Breast Implants During Breast Cancer Treatment

The risk of developing breast implant–associated anaplastic large-cell lymphoma (ALCL) could be higher among women with breast cancer and BRCA1 or BRCA2 mutations who received textured breast implants as part of their postmastectomy reconstructive surgery compared with patients lacking the genetic...

head and neck cancer

Study Defines Divergent Molecular Pathways in HPV-Associated vs HPV-Independent Sinonasal Cancers

Findings from a comprehensive genome-wide study of sinonasal squamous cell carcinomas demonstrated that human papillomavirus (HPV) can drive tumorigenesis in some cases, and these tumors exhibit similar mutational patterns to those seen in HPV-associated cervical and head and neck squamous cell...

hematologic malignancies

Case 3: Managing Myelofibrosis Beyond the First-Line Setting

This is Part 3 of Expert Perspectives on the Treatment of High-Risk Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Abdulraheem Yacoub, Gabriela Hobbs, and Douglas Tremblay discuss the treatment of a 70-year-old ...

Case 2: Recognizing Cytopenias and Comorbidities in the First-Line Management of Myelofibrosis

This is Part 2 of Expert Perspectives on the Treatment of High-Risk Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.     In this video, Drs. Abdulraheem Yacoub, Gabriela Hobbs, and Douglas Tremblay discuss the treatment of a...

hematologic malignancies

Case 1: Initial Management of a Patient With High-Risk Myelofibrosis

This is Part 1 of Expert Perspectives on the Treatment of High-Risk Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Abdulraheem Yacoub, Gabriela Hobbs, and Douglas Tremblay discuss the treatment of a 67-year-old ...

leukemia

Revumenib in Triplet Regimen Under Study in Newly Diagnosed AML With NPM1/KMT2A Alterations

A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid leukemia (AML) and an NPM1 mutation or KMT2A rearrangement. The regimen was also shown to be safe in updated results from ...

hematologic malignancies

Early Results for CAR T-Cell Therapy in Relapsed or Refractory AL Amyloidosis

Initial early results were seen for the use of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory amyloid light-chain (AL) amyloidosis in the NEXICART-2 trial. This was the first U.S. trial of CAR T-cell therapy for patients with AL amyloidosis, demonstrating...

breast cancer

Erika Hamilton, MD, on ER-Positive HER2-Negative Advanced Breast Cancer: Vepdegestrant vs Fulvestrant

Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, reviews data from the global, randomized, phase III VERITAC-2 study, which compared vepdegestrant, an oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor degrader, to fulvestrant among patients with...

prostate cancer

Gerhardt Attard, MD, PhD, on a Novel Regimen for Metastatic Castration-Sensitive Prostate Cancer With HRR Alterations

Gerhardt Attard, MD, PhD, of the Cancer Institute, University College London, presents findings from the phase III AMPLITUDE trial, which looked at the combination of niraparib and abiraterone acetate plus prednisone for patients with metastatic castration-sensitive prostate cancer with alterations ...

prostate cancer

Patient-Reported Outcomes and Symptomatic Skeletal Events With Lu-PSMA in Progressive Metastatic Castration-Resistant Prostate Cancer

In analyses from the phase III PSMAfore trial reported in The Lancet Oncology, Fizazi et al examined whether [177Lu]Lu–PSMA-617 (vipivotide tetraxetan; Lu-PSMA) improved patient-reported outcomes and delayed the time to first symptomatic skeletal events vs change of androgen receptor pathway (ARP)...

lung cancer

Neoadjuvant PD-1/PD-L1 Inhibition Plus Chemotherapy in Borderline-Resectable or Unresectable Stage III NSCLC

In a retrospective cohort study reported in JAMA Oncology, Ricciuti et al examined whether neoadjuvant PD-1/PD-L1 inhibition plus platinum-based chemotherapy showed activity in patients with borderline-resectable/unresectable stage III non–small cell lung cancer (NSCLC). Study Details The study...

gastrointestinal cancer
cardio-oncology

Do the Benefits of Fluoropyrimidine for GI Cancers Outweigh Cardiovascular Risk?

Patients with gastrointestinal cancer treated with fluoropyrimidine chemotherapy benefit from an almost eightfold reduction in the risk of all-cause mortality, despite a slight increase in the risk for cardiovascular toxicity, according to recent findings published by Abiodun et al in JACC:...

head and neck cancer

Concurrent vs Sequential Pembrolizumab With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Zandberg et al compared sequential vs concurrent pembrolizumab with chemoradiotherapy (CRT) in patients with locally advanced head and neck squamous cell carcinoma. Study Details In the U.S. multicenter noncomparative trial, 80...

colorectal cancer

Colorectal Cancer Screening: CT Colonography vs Stool Testing

Computed tomography (CT) colonography demonstrated greater clinical efficacy and cost savings than stool DNA testing for colorectal cancer screening, according to results of a study published in Radiology.   "Among the safe, minimally invasive colorectal cancer screening options, CT colonography is ...

head and neck cancer
immunotherapy

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable, Locally Advanced Head and Neck Cancer

Yesterday, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for adults with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [combined positive score (CPS) ≥ 1] as determined by an FDA-approved test, as a single agent ...

geriatric oncology
supportive care
global cancer care

Could A Telehealth Program Enhance Geriatric Cancer Care?

A telehealth-based care program may improve daily functioning, mood, disease understanding, and quality of life among older adults with cancer, according to a recent study published by Bergerot et al in JNCCN–Journal of the National Comprehensive Cancer Network. Study Methods and Results...

gastrointestinal cancer

Ramucirumab Beyond Progression Plus Irinotecan in Ramucirumab-Refractory Advanced Gastric Cancer

In a Japanese phase III trial (RINDBeRG) reported in the Journal of Clinical Oncology, Sakai et al assessed whether the addition of ramucirumab to irinotecan would improve overall survival in third- or later-line treatment of patients with advanced or recurrent gastric or gastroesophageal cancer...

colorectal cancer

Reduced-Dose Chemoradiotherapy in Early-Stage Anal Cancer

In a UK phase II trial (PLATO-ACT4) reported in The Lancet Oncology, Gilbert et al compared short-term response rates with standard- vs reduced-dose chemoradiotherapy in patients with localized squamous cell carcinoma of the anus. Study Details In the multicenter, open-label, noncomparative trial,...

gynecologic cancers

Relacorilant and Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

In the phase III ROSELLA trial—reported at the 2025 ASCO Annual Meeting as well as in The Lancet—Olawaiye et al examined the survival benefit of adding relacorilant to nab-paclitaxel in women with platinum-resistant ovarian cancer. Relacorilant is a first-in-class selective glucocorticoid receptor...

bladder cancer

FDA Approves Mitomycin Intravesical Solution for Recurrent Low-Grade Intermediate-Risk Non–Muscle-Invasive Bladder Cancer

On June 12, 2025, the U.S. Food and Drug Administration (FDA) approved mitomycin intravesical solution (Zusduri) for adult patients with recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer. Mitomycin intravesical solution is a reverse thermal hydrogel formulation of mitomycin...

issues in oncology

CancerCare Survey Reveals How Insurance Red Tape Impacts Cancer Treatment Delays

Findings from a first-of-its-kind national survey are included in “The Health Insurance Maze: How Cancer Patients Get Lost in the Red Tape of Utilization Management,” a new report from CancerCare which details the impact that prior authorization requirement and coverage stoppages have on patients...

pancreatic cancer

Cell-Free DNA Fragmentomics–Based Model for Early Detection of Pancreatic Cancer

In a Chinese study reported in the Journal of Clinical Oncology, Yin et al attempted to develop a cell-free DNA (cfDNA) fragmentomics–based model for early detection of pancreatic ductal adenocarcinoma.   Study Details The study consisted of training and validation cohorts from several Chinese...

lung cancer

Resectable NSCLC: Overall Survival With Neoadjuvant Nivolumab Plus Chemotherapy

In an analysis from the phase III CheckMate 816 trial reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Forde et al examined overall survival outcomes with the addition of neoadjuvant nivolumab to platinum-based chemotherapy in patients with stage IB to IIIA...

Advertisement

Advertisement




Advertisement